https://pubmed.ncbi.nlm.nih.gov/32473319/?
doi: 10.1016/j.diagmicrobio.2020.115071.Online ahead of print.
Evaluation of the Role of Oral Penicillin for Treating Lyme Disease Patients With Erythema Migrans in the United States
- PMID: 32473319
- DOI: 10.1016/j.diagmicrobio.2020.115071
Abstract
Clinical trials of oral penicillin preparations in the United States for treating Lyme disease patients with erythema migrans are limited to 2 studies. The results of these studies demonstrated a less than optimal outcome of this treatment. However, there were serious methodologic concerns in both studies precluding the interpretation that phenoxymethylpenicillin specifically should be regarded as ineffective. Therefore, additional clinical trials should be conducted in the United States with close attention to the dose and duration of treatment that have been used very successfully in Europe.
____________________
**Comment**
I got news for you: there are serous methodologic concerns with most studies on Lyme – particularly regarding treatment. To hear it from the very people in charge of those studies is a bit like the pot calling the kettle black.
The next all important question is why are they even attempting to treat the rash? The rash is just an outward sign of a inner systemic infection and just because you eliminate the rash doesn’t mean the inner systemic infection is gone. So, no, we don’t need more research on this. What we need is research on how to clear the infection once and for all. Please note Wormser and Strle are behind this continuing focus on the rash and the acute phase of Lyme.
Move on gentlemen, this is a waste of money and time, and doesn’t help patients one iota.
Madison Area Lyme Support Group 